DENVER—State and federal spending to combat diabetes decreased slightly in 2013 compared to the previous year, according to a new report from the National Conference of State Legislatures (NCSL). The report, "States Address the Costs of Diabetes: A 50-State Budget Survey for Fiscal Year 2013," tracks the funds specifically appropriated by state legislatures for diabetes in FY 2013. It also reviews the funding provided by the Centers for Disease Control and Prevention (CDC) to states in FY 2012 for Diabetes Prevention and Control Programs (DPCPs), as well as changes in grant funds received from the CDC.
The total of state and federal funding appropriated by state legislatures specifically for diabetes prevention and control was $11,347,038 in FY 2013, compared to $11,947,129 in FY 2012, a difference of about 5 percent. Those figures, however, do not represent total spending by states on diabetes. The CDC also supports state efforts through grant programs, providing roughly $27 million per year.
“Compelling evidence exists that diabetes, especially among children and young adults, is increasing at a rate that is not being met by state and federal funding allocations,” says Delegate Don Perdue (D) of the West Virginia House of Delegates and co-chair of NCSL’s Committee on Health and Human Services. “Diabetes is an aggressive disease that should be met with consistent and aggressive response, both in terms of policy and funding mechanisms.”
NCSL reports that nationwide, total spending by all consumers and health-care purchasers on direct medical costs for diabetes totaled in $176 billion in 2012.
According to the National Diabetes Education Program, more than 25 million people in the United States are estimated to have diabetes, which has been linked to heart disease, hypertension and stroke, and a host of other health problems. The CDC has identified diabetes as the seventh leading cause of death in the United States.
NCSL has previously released reports for fiscal years 2011 and 2012, available in their entirety to state policymakers, the media and the interested public at no charge.
Funding for NCSL’s diabetes-focused research is supported by Novo Nordisk Inc., a company committed to changing the way diabetes is treated.
NCSL is a bipartisan organization that serves the legislators and staffs of the states, commonwealths and territories. It provides research, technical assistance and opportunities for policymakers to exchange ideas on the most pressing state issues and is an effective and respected advocate for the interests of the states in the American federal system.